iBio, Inc. recently partnered with Caliber Biotherapeutics LLC to scale-up its production of materials for clinical advancement of IBIO-CFB03, the first of iBio’s proprietary anti-fibrosis products. Caliber’s production capabilities will be used for IND-enabling toxicology assessment studies and to start human clinical trials of IBIO-CFB03.
iBio is the exclusive worldwide licensee of patents that were developed by Carol Feghali-Bostwick to address therapy against fibrotic diseases. The inventor and researcher of IBIO-CFB03 is partnering with iBio for the advancement of several applications of her own invention in order to address diseases such as systemic sclerosis, scleroderma and idiopathic pulmonary fibrosis. She is a Professor of Medicine in the Division of Rheumatology and Immunology at the Medical University of South Carolina and the Kitty Trask Holt Endowed Chair. iBio expects to conduct the first human clinical trials of IBIO-CFB03 at Medical University of South Carolina.
In 2014, iBio began an exclusive technology collaboration with Novici Biotech LLC, which expanded iBio’s fibrosis therapeutics program thanks to a combination of the force of iBio’s proprietary iBioLaunch platform with Novici’s patented optimization technology. iBio engaged CBR International Corporation for clinical and strategic regulatory services and assembled a Clinical Advisory Board of internationally renowned experts in fibrotic illnesses to assist the firm in clinical product advancement and in designing human trials.
“Our engagement of Caliber, which has pilot and full-scale production capabilities, enables us to satisfy all of our production needs for human clinical trials of IBIO-CFB03,” noted the iBio’s President, Robert Erwin.
Located in College Station, Texas, Caliber operates the largest plant-made pharmaceutical protein manufacturing facility of the world. The company’s operations and facilities have been supported by the Cancer Prevention and Research Institution of Texas (CPRIT), the United Stated Defense Advanced Research Projects Agency (DARPA) and other Texas based investors. Caliber is a licensee of iBioLaunch technology for both commercial development and research purposes of other product candidates. Another license for iBioLaunch technology was also granted to Caliber by iBio to produce antibodies that target the Ebola virus, and is currently engaged in a partnership with Novici and Caliber for the optimization of undisclosed biotherapeutics.
Other News Concerning iBio’s IBIO-CFB03
iBio, Inc., a specialist in developing plant-based therapeutics, hosted shareholders and attendees at its Annual Meeting on Thursday, December 11, and presented a comprehensive update on the company’s ongoing activities and R&D progress for one of their lead pipeline products, IBIO-CFB03, formulated to treat fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc).